Business
Enveric Biosciences Announces Registration of Five Trademarks
Canadian Trademark Office Issues House Marks to Enveric Biosciences, Inc. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric”
About this update from Enveric Biosciences, Inc.
[{"type":"text","content":"\nCanadian Trademark Office Issues House Marks to Enveric Biosciences, Inc.\n\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nEnveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the Canadian Intellectual Property Office has registered five of the Company’s trademarks, including its house marks, Enveric and Enveric Biosciences.\n\n\n“The registration of a Company’s house marks, such as our marks Enveric and Enveric Biosciences, is an important intellectual property milestone supporting our branding strategies for our future products. We thank the Canadian Intellectual Property Office for its recent action,” said Joseph Tucker, PhD, CEO of Enveric.\n\n\nIn addition, the Canadian Intellectual Property Office registered two “Plus Marks” which are designs used on Enveric product packaging, and its trademark, “Next Generation Mental Health.” Dr. Tucker continued, “These additional marks reflect the Company’s view of the expected positive impact of its pipeline products under development on mental health, including the lead molecule EB-003, for which an IND filing with the FDA is planned in 2026.”\n\n\nDr. Tucker concluded: “Registration of the house marks, Enveric and Enveric Biosciences, in the United States and now in Canada, along with existing registrations of the mark, Enveric, in Europe and the U.K. helps secure our branding strategy in these important future markets of interest for EB-003.”\n\n\nAbout Enveric Biosciences\n\n\nEnveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of patent protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric’s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT₂A and 5-HT₁B receptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.\n\n\nFor more information, please visit www.enveric.com.\n\n\...